Specialty Pharmacy

Health systems individually have struggled to demonstrate improvements to total cost of care because, without data about patients they do not serve, they cannot define a comparison group.

One mutated version of KRAS that commonly arises in cancer cells is called KRAS(G12C) and it produces a mutated KRAS protein that allows the cells to grow and spread in the body.

The study shows that brentuximab vedotin allowed for reduced radiation exposures and resulted in fewer adverse effects for patients, according to its authors.

Pharmacy Times spoke with spinal muscular atrophy (SMA) patient Nick Sinagra about his treatment journey and his experiences with 2 different SMA treatments.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

A new study led by researchers at NYU Rory Meyers College of Nursing found that breast cancer survivors with a higher risk of cancer recurrence based on genomic testing may experience greater fear of their cancer returning.

Nivolumab is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival compared to chemotherapy alone in this patient population.

Hematology/Oncology Pharmacy Association plans to develop tools and resources to support those conducting research in the oncology pharmacy field, with the goal of promoting pharmacist-led research and improving the ability to analyze difficult scientific questions.

Ependymoma is a rare type of tumor that develops in the brain or spinal cord and can occur at any age, but occurs most frequently in young children.

Promising investigational oncology drugs include oral taxanes, small molecule drugs, and immunotherapies.

Common factors that contributed to reported increased dissatisfaction at work include role conflict, quantity of work, workflow disruptions, organizational culture, and leadership support.

Even while therapeutically anticoagulated, patients with cancer have risk factors for recurring venous thromboembolism and bleeding, according to a session at the Hematology/Oncology Pharmacy Association 2021 Virtual Annual Conference.

Sacituzumab govitecan (Trodelvy) approved for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.

A session at the Hematology/Oncology Pharmacy Association Virtual Annual Conference provided an overview of how treatment options are changing with potential new therapies in development for patients with non-small cell lung cancer.

During the initial CAR T-cell therapy period, the total cost of care ranged from $350,000 to more than $2 million.

The safety profile was consistent with the profiles associated with each drug as a monotherapy, with no clinically significant drug-drug interactions observed with the combination.

In a presentation at the Community Oncology Alliance 2021 Virtual Conference, Jeff Sharman, MD, summarized the most important developments in care for CLL.

Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.

A new study published in Nature Communications used artificial intelligence (AI) to identify 3 new multiple sclerosis (MS) subtypes, which may help identify which individuals are more likely to have disease progression, according to the authors.

The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program immediately after their diagnosis had, on average, 70% less chance of having lingering leukemia cells after a month of chemotherapy than those not on the diet-and-exercise regimen.

In the United States, non–small cell lung cancer accounts for 80% to 85% of all lung cancers, with most patients initially diagnosed with advanced or metastatic disease.

The first step toward operationalizing the uptake of biosimilars is having a program-level discussion that not only describes what biosimilars are, but also assesses how they impact the bottom line and could get incorporated into treatment plans.

Opdivo-based combinations show benefit for patients with esophageal cancer who are often diagnosed after their disease has spread and would benefit from new therapeutic options.

Findings from the phase 3 ASCENT trial demonstrate a clinically meaningful 57% reduction in the risk of disease worsening or death for patients receiving sacituzumab govitecan.

Health System Owned Specialty Pharmacy Alliance issues open letter outlining three needed industry actions to improve patient care and outcomes.

In April 2020, colonoscopy screenings declined from 15.1 per 10,000 beneficiaries to 0.9, a 95% difference.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

The researchers analyzed millions of pharmacy transactions by more than 600,000 people in the United States from 2017 to 2019 in order to get a better sense of how vouchers and other point-of-sale co-payment offsets are used.

Isatuximab in combination with carfilzomib and dexamethasone reduced the risk of disease progression or death by 45% versus standard of care alone.

March 31 is International Transgender Day of Visibility, and the Human Rights Campaign (HRC) Foundation and the American Pharmacists Association (APhA) partnered to release a new guide for pharmacies on transgender and gender-diverse inclusion.